Literature DB >> 17683483

A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine.

David J Eyerman1, Bryan K Yamamoto.   

Abstract

Methamphetamine (METH) produces long-term decreases in markers of dopamine (DA) terminals in animals and humans. A decrease in the function of the vesicular monoamine transporter 2 (VMAT2) has been associated with damage to striatal DA terminals caused by METH; however, a possible mechanism for this decrease in VMAT2 function has not been defined. The current study showed that METH caused a rapid decrease to 68% of controls in VMAT2 protein immunoreactivity of the vesicular fraction from striatal synaptosomes within 1 h after a repeated high-dose administration regimen of METH. This decrease was associated with a 75% increase in nitrosylation of VMAT2 protein in the synaptosomal fraction as measured by nitrosocysteine immunoreactivity of VMAT2 protein. The rapid decreases in VMAT2 persisted when evaluated 7 days later and were illustrated by decreases in VMAT2 immunoreactivity and DA content of the vesicular fraction to 34% and 51% of control values, respectively. The decreases were blocked or attenuated by prior injections of the neuronal nitric oxide synthase inhibitor, S-methyl-l-thiocitrulline. These studies demonstrate that METH causes a rapid neuronal nitric oxide synthase-dependent oxidation of VMAT2 and long-term decreases in VMAT2 protein and function. The results also suggest that surviving DA terminals after METH exposure may have a compromised capacity to buffer cytosolic DA concentrations and DA-derived oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17683483     DOI: 10.1111/j.1471-4159.2007.04837.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  42 in total

1.  The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.

Authors:  Joshua S Beckmann; Emily D Denehy; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-21       Impact factor: 4.530

2.  Methamphetamine-induced oxidation of proteins and alterations in protein processing.

Authors:  Bryan K Yamamoto; Fu-Chen Yang
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

3.  Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.

Authors:  Pei-Wen Chu; Gregory C Hadlock; Paula Vieira-Brock; Kristen Stout; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2010-08-25       Impact factor: 5.372

4.  Unique genetic factors influence sensitivity to the rewarding and aversive effects of methamphetamine versus cocaine.

Authors:  Noah R Gubner; Cheryl Reed; Carrie S McKinnon; Tamara J Phillips
Journal:  Behav Brain Res       Date:  2013-08-28       Impact factor: 3.332

5.  Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Paula L Vieira-Brock; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2015-01-31       Impact factor: 5.250

6.  Genetically correlated effects of selective breeding for high and low methamphetamine consumption.

Authors:  J M Wheeler; C Reed; S Burkhart-Kasch; N Li; C L Cunningham; A Janowsky; F H Franken; K M Wiren; J G Hashimoto; A C Scibelli; T J Phillips
Journal:  Genes Brain Behav       Date:  2009-07-21       Impact factor: 3.449

Review 7.  Glutathione and redox signaling in substance abuse.

Authors:  Joachim D Uys; Patrick J Mulholland; Danyelle M Townsend
Journal:  Biomed Pharmacother       Date:  2014-06-24       Impact factor: 6.529

8.  N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.

Authors:  B Torres; A E Ruoho
Journal:  Neuroscience       Date:  2013-12-07       Impact factor: 3.590

Review 9.  Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.

Authors:  Annette E Fleckenstein; Trent J Volz; Glen R Hanson
Journal:  Neuropharmacology       Date:  2008-07-10       Impact factor: 5.250

10.  Chronic wheel running reduces maladaptive patterns of methamphetamine intake: regulation by attenuation of methamphetamine-induced neuronal nitric oxide synthase.

Authors:  Alexander J Engelmann; Mark B Aparicio; Airee Kim; Jeffery C Sobieraj; Clara J Yuan; Yanabel Grant; Chitra D Mandyam
Journal:  Brain Struct Funct       Date:  2013-02-27       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.